CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2

Pharmacologically difficult targets, such as MYC transcription factors, represent a major challenge in cancer therapy. For the childhood cancer neuroblastoma, amplification of the oncogene MYCN is associated with high-risk disease and poor prognosis. Here, we deployed genome-scale CRISPR-Cas9 screening of MYCN-amplified neuroblastoma and found a preferential dependency on genes encoding the polycomb repressive complex 2 (PRC2) components EZH2, EED, and SUZ12. Genetic and pharmacological suppression of EZH2 inhibited neuroblastoma growth in vitro and in vivo. Moreover, compared with neuroblastomas without MYCN amplification, MYCN-amplified neuroblastomas expressed higher levels of EZH2. ChIP analysis showed that MYCN binds at the EZH2 promoter, thereby directly driving expression. Transcriptomic and epigenetic analysis, as well as genetic rescue experiments, revealed that EZH2 represses neuronal differentiation in neuroblastoma in a PRC2-dependent manner. Moreover, MYCN-amplified and high-risk primary tumors from patients with neuroblastoma exhibited strong repression of EZH2-regulated genes. Additionally, overexpression of IGFBP3, a direct EZH2 target, suppressed neuroblastoma growth in vitro and in vivo. We further observed strong synergy between histone deacetylase inhibitors and EZH2 inhibitors. Together, these observations demonstrate that MYCN upregulates EZH2, leading to inactivation of a tumor suppressor program in neuroblastoma, and support testing EZH2 inhibitors in patients with MYCN-amplified neuroblastoma.

[1]  T. Shimamura,et al.  PRC2-Mediated Transcriptomic Alterations at the Embryonic Stage Govern Tumorigenesis and Clinical Outcome in MYCN-Driven Neuroblastoma. , 2017, Cancer research.

[2]  Ann E. Sizemore,et al.  Computational correction of copy-number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells , 2017, Nature Genetics.

[3]  R. Versteeg,et al.  Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity. , 2017, European journal of cancer.

[4]  Kaitlyn M. Gayvert,et al.  N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. , 2016, Cancer cell.

[5]  Ralf Herwig,et al.  Analyzing and interpreting genome data at the network level with ConsensusPathDB , 2016, Nature Protocols.

[6]  David J. Duffy,et al.  Integrative Genome-Scale Analysis Identifies Epigenetic Mechanisms of Transcriptional Deregulation in Unfavorable Neuroblastomas. , 2016, Cancer research.

[7]  T. Golub,et al.  Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting. , 2016, Cancer discovery.

[8]  R. Bernards,et al.  CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes , 2016, Nature Biotechnology.

[9]  O. Fernandez-Capetillo,et al.  A Genome-wide CRISPR Screen Identifies CDC25A as a Determinant of Sensitivity to ATR Inhibitors. , 2016, Molecular cell.

[10]  R. Elkon,et al.  Functional genetic screens for enhancer elements in the human genome using CRISPR-Cas9 , 2016, Nature Biotechnology.

[11]  Meagan E. Sullender,et al.  Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9 , 2015, Nature Biotechnology.

[12]  Henry W. Long,et al.  Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer. , 2016, Cancer discovery.

[13]  S. Robinson,et al.  Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma. , 2016, Cancer cell.

[14]  G. Tonini,et al.  Multi-omic profiling of MYCN-amplified neuroblastoma cell-lines , 2015, Genomics Data.

[15]  Thomas P. Howard,et al.  SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2 , 2015, Nature Medicine.

[16]  E. Lander,et al.  Identification and characterization of essential genes in the human genome , 2015, Science.

[17]  Joshua A. Bittker,et al.  Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. , 2015, Cancer discovery.

[18]  Sam Michael,et al.  High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations , 2015, Scientific Reports.

[19]  B. Weir,et al.  Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma , 2015, Oncotarget.

[20]  Chun Jimmie Ye,et al.  A Genome-wide CRISPR Screen in Primary Immune Cells to Dissect Regulatory Networks , 2015, Cell.

[21]  Marie-Agnès Dillies,et al.  SARTools: A DESeq2- and EdgeR-Based R Pipeline for Comprehensive Differential Analysis of RNA-Seq Data , 2015, bioRxiv.

[22]  Chin-Lee Wu,et al.  EZH2 promotes tumor progression via regulating VEGF-A/AKT signaling in non-small cell lung cancer. , 2015, Cancer letters.

[23]  Benjamin G. Bitler,et al.  Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers , 2015, Nature Medicine.

[24]  P. Gestraud,et al.  Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypes. , 2014, Cell reports.

[25]  Bandana Sharma,et al.  CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer , 2014, Cell.

[26]  Adam Kiezun,et al.  Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma , 2014, Proceedings of the National Academy of Sciences.

[27]  David P. Kreil,et al.  The concordance between RNA-seq and microarray data depends on chemical treatment and transcript abundance , 2014, Nature Biotechnology.

[28]  K. Ross,et al.  Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma , 2014, Oncotarget.

[29]  L. Pfeffer,et al.  MicroRNA-21 Promotes Glioblastoma Tumorigenesis by Down-regulating Insulin-like Growth Factor-binding Protein-3 (IGFBP3)* , 2014, The Journal of Biological Chemistry.

[30]  Fidel Ramírez,et al.  deepTools: a flexible platform for exploring deep-sequencing data , 2014, Nucleic Acids Res..

[31]  Rory Stark,et al.  Impact of artifact removal on ChIP quality metrics in ChIP-seq and ChIP-exo data , 2014, Front. Genet..

[32]  Neville E. Sanjana,et al.  Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.

[33]  E. Lander,et al.  Genetic Screens in Human Cells Using the CRISPR-Cas9 System , 2013, Science.

[34]  Wei Shi,et al.  featureCounts: an efficient general purpose program for assigning sequence reads to genomic features , 2013, Bioinform..

[35]  G. Ganji,et al.  BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models , 2013, PloS one.

[36]  Bruno Di Stefano,et al.  Polycomb complexes in stem cells and embryonic development , 2013, Development.

[37]  S. Armstrong,et al.  Recent progress toward epigenetic therapies: the example of mixed lineage leukemia. , 2013, Blood.

[38]  Giovanni Roti,et al.  Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation. , 2013, Chemistry & biology.

[39]  David A. Orlando,et al.  Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers , 2013, Cell.

[40]  K. Stegmaier,et al.  Targeting MYCN in neuroblastoma by BET bromodomain inhibition. , 2013, Cancer discovery.

[41]  G. Perini,et al.  Physical Interaction between MYCN Oncogene and Polycomb Repressive Complex 2 (PRC2) in Neuroblastoma , 2013, The Journal of Biological Chemistry.

[42]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .

[43]  Cole Trapnell,et al.  TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions , 2013, Genome Biology.

[44]  M. Loda,et al.  EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent , 2012, Science.

[45]  Yan Liu,et al.  EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations , 2012, Nature.

[46]  Yue Zhang,et al.  The Loop Position of shRNAs and Pre-miRNAs Is Critical for the Accuracy of Dicer Processing In Vivo , 2012, Cell.

[47]  Joaquín Dopazo,et al.  Qualimap: evaluating next-generation sequencing alignment data , 2012, Bioinform..

[48]  Yong Zhang,et al.  Identifying ChIP-seq enrichment using MACS , 2012, Nature Protocols.

[49]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[50]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[51]  J. Khan,et al.  EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR. , 2012, Cancer research.

[52]  G. Ganji,et al.  EZH 2 inhibition as a therapeutic strategy for lymphoma with EZH 2-activating mutations , 2012 .

[53]  K. Döhner,et al.  Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. , 2012, Blood.

[54]  Qiang Yu,et al.  Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers. , 2011, Molecular cell.

[55]  Ralf Herwig,et al.  ConsensusPathDB: toward a more complete picture of cell biology , 2010, Nucleic Acids Res..

[56]  J. Khan,et al.  EZH 2 Mediates Epigenetic Silencing of Neuroblastoma Suppressor Genes CASZ 1 , CLU , RUNX 3 , and NGFR , 2011 .

[57]  B. Langmead,et al.  Aligning Short Sequencing Reads with Bowtie , 2010, Current protocols in bioinformatics.

[58]  Gary D Bader,et al.  Enrichment Map: A Network-Based Method for Gene-Set Enrichment Visualization and Interpretation , 2010, PloS one.

[59]  N. Cheung,et al.  Neuroblastoma: Therapeutic strategies for a clinical enigma. , 2010, Cancer treatment reviews.

[60]  C. Glass,et al.  Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. , 2010, Molecular cell.

[61]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[62]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[63]  R. Beijersbergen,et al.  Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. , 2009, Cancer cell.

[64]  Ralf Herwig,et al.  ConsensusPathDB—a database for integrating human functional interaction networks , 2008, Nucleic Acids Res..

[65]  Seungjin Choi,et al.  Independent Component Analysis , 2009, Handbook of Natural Computing.

[66]  A. Durán,et al.  Protein Kinase C (cid:2) Represses the Interleukin-6 Promoter and Impairs Tumorigenesis In Vivo (cid:1) † , 2008 .

[67]  Gudrun Schleiermacher,et al.  Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma , 2008, Nature.

[68]  Robert Clarke,et al.  Knowledge-guided multi-scale independent component analysis for biomarker identification , 2008, BMC Bioinformatics.

[69]  Huai Li,et al.  Unraveling transcriptional regulatory programs by integrative analysis of microarray and transcription factor binding data , 2008, Bioinform..

[70]  Pierre-Antoine Absil,et al.  Elucidating the Altered Transcriptional Programs in Breast Cancer using Independent Component Analysis , 2007, PLoS Comput. Biol..

[71]  Jing Liang,et al.  Integration of Estrogen and Wnt Signaling Circuits by the Polycomb Group Protein EZH2 in Breast Cancer Cells , 2007, Molecular and Cellular Biology.

[72]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[73]  D. Rowitch,et al.  Neuroblastoma Mycn Protein and Blocks Malignant Progression in Inhibition of Phosphatidylinositol 3-Kinase Destabilizes , 2006 .

[74]  David Lindgren,et al.  Independent component analysis reveals new and biologically significant structures in micro array data , 2006, BMC Bioinformatics.

[75]  O. Halvorsen,et al.  EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[77]  David P. Kreil,et al.  Independent component analysis of microarray data in the study of endometrial cancer , 2004, Oncogene.

[78]  L. Di Marcotullio,et al.  REN(KCTD11) is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[79]  Chiara Sabatti,et al.  Network component analysis: Reconstruction of regulatory signals in biological systems , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[80]  Pinchas Cohen,et al.  Interaction between the Alzheimer's survival peptide humanin and insulin-like growth factor-binding protein 3 regulates cell survival and apoptosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[81]  Debashis Ghosh,et al.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[82]  M. Hofker.  Faculty Opinions recommendation of PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. , 2003 .

[83]  G. Brodeur.  Neuroblastoma: biological insights into a clinical enigma , 2003, Nature Reviews Cancer.

[84]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[85]  Hengbin Wang,et al.  Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing , 2002, Science.

[86]  Pinchas Cohen,et al.  Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer. , 2002, Cancer research.

[87]  Aapo Hyvärinen,et al.  Fast and robust fixed-point algorithms for independent component analysis , 1999, IEEE Trans. Neural Networks.

[88]  G. Mohapatra,et al.  Targeted expression of MYCN causes neuroblastoma in transgenic mice , 1997, The EMBO journal.

[89]  Pierre Comon,et al.  Independent component analysis, A new concept? , 1994, Signal Process..

[90]  G. Thomas,et al.  Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours , 1992, Nature.

[91]  I. Jolliffe.  Principal Component Analysis and Factor Analysis , 1986 .

[92]  H. Sather,et al.  Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. , 1985, The New England journal of medicine.

[93]  M. Israel,et al.  Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma , 1985, Nature.

[94]  H. Varmus,et al.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. , 1984, Science.

[95]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[96]  J. Trent,et al.  Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour , 1983, Nature.

[97]  C. I. Bliss.  The calculation of microbial assays. , 1956, Bacteriological reviews.

[98]  Karl Pearson F.R.S..  LIII. On lines and planes of closest fit to systems of points in space , 1901 .